Omnicell, Inc. (NASDAQ:OMCL) Short Interest Down 15.7% in January

Omnicell, Inc. (NASDAQ:OMCL) was the target of a significant drop in short interest during the month of January. As of January 30th, there was short interest totaling 2,259,277 shares, a drop of 15.7% from the January 15th total of 2,680,297 shares. Approximately 5.2% of the shares of the stock are sold short. Based on an average trading volume of 335,834 shares, the short-interest ratio is presently 6.7 days. Based on an average trading volume of 335,834 shares, the short-interest ratio is presently 6.7 days. Approximately 5.2% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

A number of research firms have commented on OMCL. KeyCorp raised shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price objective for the company in a report on Wednesday, January 7th. Zacks Research downgraded Omnicell from a “hold” rating to a “strong sell” rating in a research note on Monday, February 9th. Bank of America raised Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 price objective for the company in a report on Wednesday, February 4th. Weiss Ratings raised Omnicell from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, February 9th. Finally, Piper Sandler reissued an “overweight” rating and set a $49.00 price target (down from $63.00) on shares of Omnicell in a research report on Friday, February 6th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Omnicell has an average rating of “Moderate Buy” and an average target price of $54.50.

Omnicell Price Performance

Shares of NASDAQ OMCL opened at $36.50 on Monday. The stock has a market cap of $1.64 billion, a P/E ratio of 912.73, a P/E/G ratio of 1.35 and a beta of 0.78. The firm’s 50-day simple moving average is $46.04 and its 200 day simple moving average is $37.40. Omnicell has a fifty-two week low of $22.66 and a fifty-two week high of $55.00. The company has a quick ratio of 1.22, a current ratio of 1.43 and a debt-to-equity ratio of 0.14.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, February 5th. The company reported $0.40 earnings per share for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.07). Omnicell had a return on equity of 3.00% and a net margin of 0.17%.The firm had revenue of $313.98 million during the quarter, compared to analyst estimates of $313.36 million. During the same quarter last year, the company earned $0.60 earnings per share. The business’s revenue for the quarter was up 2.3% on a year-over-year basis. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. Equities analysts expect that Omnicell will post 1.09 EPS for the current year.

Insider Transactions at Omnicell

In other Omnicell news, EVP Corey J. Manley sold 6,106 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $49.90, for a total value of $304,689.40. Following the completion of the transaction, the executive vice president owned 91,674 shares in the company, valued at $4,574,532.60. This represents a 6.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 2.52% of the company’s stock.

Institutional Investors Weigh In On Omnicell

Hedge funds have recently modified their holdings of the stock. Cerity Partners LLC boosted its holdings in shares of Omnicell by 4.9% in the fourth quarter. Cerity Partners LLC now owns 7,613 shares of the company’s stock worth $345,000 after buying an additional 354 shares during the period. SG Americas Securities LLC grew its position in Omnicell by 6.6% during the 3rd quarter. SG Americas Securities LLC now owns 6,433 shares of the company’s stock worth $196,000 after purchasing an additional 401 shares in the last quarter. Thrivent Financial for Lutherans raised its stake in Omnicell by 1.2% during the 2nd quarter. Thrivent Financial for Lutherans now owns 34,445 shares of the company’s stock valued at $1,013,000 after purchasing an additional 424 shares during the period. Martin & Co. Inc. TN lifted its holdings in shares of Omnicell by 0.4% in the third quarter. Martin & Co. Inc. TN now owns 121,720 shares of the company’s stock valued at $3,706,000 after purchasing an additional 443 shares in the last quarter. Finally, Legal & General Group Plc boosted its position in shares of Omnicell by 0.3% in the third quarter. Legal & General Group Plc now owns 158,399 shares of the company’s stock worth $4,823,000 after buying an additional 448 shares during the period. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.